Published in J Transl Med on March 23, 2013
γ-Tubulin complexes in microtubule nucleation and beyond. Mol Biol Cell (2015) 0.86
Centrosome associated genes pattern for risk sub-stratification in multiple myeloma. J Transl Med (2016) 0.75
Centrosome aberrations: cause or consequence of cancer progression? Nat Rev Cancer (2002) 4.88
Centrosome amplification drives chromosomal instability in breast tumor development. Proc Natl Acad Sci U S A (2002) 3.81
Requirement of a centrosomal activity for cell cycle progression through G1 into S phase. Science (2001) 3.56
Centrosome defects and genetic instability in malignant tumors. Cancer Res (1998) 3.32
Genomic instability in Gadd45a-deficient mice. Nat Genet (1999) 3.01
Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood (1993) 2.98
Oncogenes and tumour suppressors take on centrosomes. Nat Rev Cancer (2007) 2.87
"It takes two to tango": understanding how centrosome duplication is regulated throughout the cell cycle. Genes Dev (2001) 2.46
Four-dimensional control of the cell cycle. Nat Cell Biol (1999) 2.44
Genomic changes defining the genesis, progression, and malignancy potential in solid human tumors: a phenotype/genotype correlation. Genes Chromosomes Cancer (1999) 2.19
DNA-replication/DNA-damage-dependent centrosome inactivation in Drosophila embryos. Nat Cell Biol (2000) 2.13
Duplication of ATR inhibits MyoD, induces aneuploidy and eliminates radiation-induced G1 arrest. Nat Genet (1998) 2.04
The centrosome in vertebrates: more than a microtubule-organizing center. Trends Cell Biol (2001) 1.98
Altered centrosome structure is associated with abnormal mitoses in human breast tumors. Am J Pathol (1999) 1.82
Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica (2010) 1.73
Correlation between centrosome abnormalities and chromosomal instability in human pancreatic cancer cells. Cancer Genet Cytogenet (2001) 1.60
The centrosome cycle. FEBS Lett (2002) 1.51
Combined measurement of plasma cell proliferative and apoptotic index in multiple myeloma defines patients with good and poor prognosis. Leuk Res (2010) 1.45
Integration of the centrosome in cell cycle control, stress response and signal transduction pathways. Curr Opin Cell Biol (2002) 1.35
Centrosome replication, genomic instability and cancer. Leukemia (2002) 1.31
The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition. Blood (2007) 1.29
Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. Blood (1988) 1.21
Centrosome abnormalities, genomic instability and carcinogenic progression. Biochim Biophys Acta (2001) 1.19
Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy. Br J Haematol (1984) 1.12
Clinical implication of centrosome amplification in plasma cell neoplasm. Blood (2005) 1.11
Suppression of centrosome amplification after DNA damage depends on p27 accumulation. Cancer Res (2006) 1.10
Centrosome amplification in tumorigenesis. Cancer Lett (2012) 1.07
Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders. Br J Haematol (1999) 1.05
A possible role for centrosome overduplication in radiation-induced cell death. Oncogene (2000) 1.04
Stepwise progression of centrosome defects associated with local tumor growth and metastatic process of human pancreatic carcinoma cells transplanted orthotopically into nude mice. Lab Invest (2001) 1.01
Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial. Leuk Lymphoma (2011) 0.96
A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death. Blood (2001) 0.93
Human papillomavirus infection, centrosome aberration, and genetic stability in cervical lesions. Mod Pathol (2001) 0.91
A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood (1995) 0.91
A cell cycle hypothesis of cooperative oncogenesis (Review). Int J Oncol (2007) 0.84
Centrosome amplification as a possible marker of mitotic disruptions and cellular carcinogenesis in multiple myeloma. Leuk Res (2010) 0.80
Genomics in multiple myeloma research. Klin Onkol (2011) 0.79
Visualization of numerical centrosomal abnormalities by immunofluorescent staining. Klin Onkol (2011) 0.77
Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med (2012) 5.16
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med (2014) 5.08
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol (2007) 3.54
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood (2011) 3.07
Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood (2008) 2.12
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol (2013) 1.99
Anesthesia for cesarean delivery in the Czech Republic: a 2011 national survey. Anesth Analg (2015) 1.94
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica (2014) 1.57
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol (2014) 1.52
Induction treatment of light chain deposition disease with bortezomib: rapid hematological response with persistence of renal involvement. Leuk Lymphoma (2011) 1.49
Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. Haematologica (2012) 1.45
Extremely low-frequency electromagnetic fields disrupt magnetic alignment of ruminants. Proc Natl Acad Sci U S A (2009) 1.43
TGF-β - an excellent servant but a bad master. J Transl Med (2012) 1.41
Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia. J Clin Oncol (2011) 1.39
Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol (2010) 1.38
Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage. Blood (2009) 1.28
Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica (2013) 1.22
Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders. Br J Haematol (2010) 1.20
Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia. J Exp Med (2010) 1.15
Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma. J Clin Oncol (2012) 1.10
Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma. PLoS One (2012) 1.09
Dendritic cell vaccines in the treatment of multiple myeloma: advances and limitations. Med Oncol (2002) 1.08
Nestin expression in the cell lines derived from glioblastoma multiforme. BMC Cancer (2006) 1.03
Substrate specificity of haloalkane dehalogenases. Biochem J (2011) 1.01
Baseline characteristics and hospital mortality in the Acute Heart Failure Database (AHEAD) Main registry. Crit Care (2011) 0.97
Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial. Leuk Lymphoma (2011) 0.96
Cross-sectional transverse area and hyperintensities on magnetic resonance imaging in relation to the clinical picture in cervical spondylotic myelopathy. Spine (Phila Pa 1976) (2007) 0.95
Low-level copy number changes of MYC genes have a prognostic impact in medulloblastoma. J Neurooncol (2010) 0.95
Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. Leuk Res (2013) 0.94
Characterization of a GM7 glioblastoma cell line showing CD133 positivity and both cytoplasmic and nuclear localization of nestin. Oncol Rep (2009) 0.93
Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma. Leuk Lymphoma (2012) 0.92
Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma. J Cell Mol Med (2014) 0.92
Unusual cone and rod properties in subterranean African mole-rats (Rodentia, Bathyergidae). Eur J Neurosci (2004) 0.91
Estimation of left ventricular filling pressures by speckle tracking echocardiography in patients with idiopathic dilated cardiomyopathy. Eur J Echocardiogr (2010) 0.90
Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response. Ann Hematol (2009) 0.90
Clinical correlations of miR-21 expression in colorectal cancer patients and effects of its inhibition on DLD1 colon cancer cells. Int J Colorectal Dis (2012) 0.90
Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients. Hematol Oncol (2012) 0.90
Long-term survival following acute heart failure: the Acute Heart Failure Database Main registry (AHEAD Main). Eur J Intern Med (2012) 0.89
Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica (2013) 0.89
Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma. Int J Oncol (2011) 0.88
Serum miR-29a as a marker of multiple myeloma. Leuk Lymphoma (2012) 0.88
Functionally suppressive CD8 T regulatory cells are increased in patients with multiple myeloma: a cause for immune impairment. PLoS One (2012) 0.88
PML-RARα co-operates with Sox4 in acute myeloid leukemia development in mice. Haematologica (2012) 0.87
Clinicopathological correlations of nestin expression in surgically resectable pancreatic cancer including an analysis of perineural invasion. J Gastrointestin Liver Dis (2011) 0.87
Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients. Haematologica (2011) 0.87
MyelomA Genetics International Consortium. Leuk Lymphoma (2012) 0.86
The association between levels of tissue inhibitor of metalloproteinase-1 with acute heart failure and left ventricular dysfunction in patients with ST elevation myocardial infarction treated by primary percutaneous coronary intervention. Genet Test Mol Biomarkers (2012) 0.86
Prediabetes/early diabetes-associated neuropathy predominantly involves sensory small fibres. J Peripher Nerv Syst (2012) 0.86
Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy. Biol Blood Marrow Transplant (2010) 0.86
Mechanism of immunomodulatory drugs in multiple myeloma. Leuk Res (2012) 0.86
Dual treatment with FLT3 inhibitor SU11657 and doxorubicin increases survival of leukemic mice. Leuk Res (2006) 0.85
Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment. Clin Lymphoma Myeloma (2008) 0.85
Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma. Haematologica (2010) 0.85
Prognostic utility of biomarkers in predicting of one-year outcomes in patients with aortic stenosis treated with transcatheter or surgical aortic valve implantation. PLoS One (2012) 0.85
Changing and shielded magnetic fields suppress c-Fos expression in the navigation circuit: input from the magnetosensory system contributes to the internal representation of space in a subterranean rodent. J R Soc Interface (2010) 0.84
Cardio-ankle vascular index in subjects with dyslipidaemia and other cardiovascular risk factors. J Atheroscler Thromb (2013) 0.84
Survival and infertility treatment in male cancer patients after sperm banking. Fertil Steril (2008) 0.84
Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib. Clin Lymphoma Myeloma (2009) 0.84
Identification of 2.3-Mb gene locus for congenital aural atresia in 18q22.3 deletion: a case report analyzed by comparative genomic hybridization. Otol Neurotol (2006) 0.84
Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. Haematologica (2011) 0.84
Flow cytometry based enumeration and functional characterization of CD8 T regulatory cells in patients with multiple myeloma before and after lenalidomide plus dexamethasone treatment. Cytometry B Clin Cytom (2013) 0.83
Contrast-enhanced ultrasonography compared to gray-scale and power doppler in the diagnosis of peripheral lymphadenopathy. Eur J Radiol (2013) 0.83
Proteomic analysis in multiple myeloma research. Mol Biotechnol (2011) 0.83
Epidemiology and long-term survival of pulmonary arterial hypertension in the Czech Republic: a retrospective analysis of a nationwide registry. BMC Pulm Med (2014) 0.83
Association between laboratory markers and presence of coronary artery disease. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub (2010) 0.83
ACE gene insertion/deletion polymorphism has a mild influence on the acute development of left ventricular dysfunction in patients with ST elevation myocardial infarction treated with primary PCI. BMC Cardiovasc Disord (2010) 0.82
Age-related treatment strategy and long-term outcome in acute myocardial infarction patients in the PCI era. BMC Cardiovasc Disord (2012) 0.82
Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib. Clin Lymphoma Myeloma Leuk (2013) 0.82
The origin of deletion 22q11 in chronic lymphocytic leukemia is related to the rearrangement of immunoglobulin lambda light chain locus. Leuk Res (2013) 0.81
Light perception in two strictly subterranean rodents: life in the dark or blue? PLoS One (2010) 0.81
Identification of rare complete BRCA1 gene deletion using a combination of SNP haplotype analysis, MLPA and array-CGH techniques. Breast Cancer Res Treat (2007) 0.81
Comparison of functional fibrinogen assessment using thromboelastography with the standard von Clauss method. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub (2011) 0.81
Interdigitating dendritic cell sarcoma of the leg. Onkologie (2009) 0.81
The relationship between proliferation and apoptosis in patients with monoclonal gammopathy of undetermined significance or multiple myeloma. Haematologica (2005) 0.80
Cardio-ankle vascular index in heterozygous familial hypercholesterolemia. J Atheroscler Thromb (2012) 0.80